Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.

Saved in:
Bibliographic Details
Title: Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Authors: Werner B; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Sjoquist KM; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Espinoza D; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Yip S; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Chang G; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Cummins MM; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Mileshkin L; Peter MacCallum Cancer Centre, Melbourne, Australia., Ananda S; Peter MacCallum Cancer Centre, Melbourne, Australia; Western Health, Furlong Road, St Albans, Australia; Epworth Freemasons Hospital, East Melbourne, Australia; Department of Medicine, Western Health, University of Melbourne, Melbourne, Australia., Shannon C; Mater Cancer Care Centre, South Brisbane, Australia., Friedlander M; Prince of Wales Hospital, Sydney, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Warton K; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Ford CE; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Electronic address: caroline.ford@unsw.edu.au.
Source: Translational oncology [Transl Oncol] 2024 May; Vol. 43, pp. 101914. Date of Electronic Publication: 2024 Feb 27.
Publication Type: Journal Article
Journal Info: Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1936-5233
DOI:10.1016/j.tranon.2024.101914